A. Sinclair  Dunlop net worth and biography

A. Dunlop Biography and Net Worth

As Managing Partner of Epidarex, Mr. Dunlop leads the review and analysis of Epidarex’s investment candidates. A former international business and economics analyst with the Center for Strategic and International Studies in Washington, DC, Mr. Dunlop has private equity and venture capital experience in Europe, the US, and Israel. Prior to founding Epidarex, Mr. Dunlop acted as the Director of New Business Ventures of MASA Life Science Ventures after a period as an Associate at New Vantage Group, manager of several early-stage venture capital funds in the Mid-Atlantic region. In May 2000, Mr. Dunlop received his MBA degree from Columbia Business School, where he was the R. C. Kopf British-American Fellow in international business. He also holds an MA degree with honors in political economy from the University of Glasgow and an MA degree in International Relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University. He is a Saint Andrews Society of the State of New York Scholar.

How do I contact A. Sinclair Dunlop?

The corporate mailing address for Mr. Dunlop and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on A. Sinclair Dunlop's contact information.

Has A. Sinclair Dunlop been buying or selling shares of Apellis Pharmaceuticals?

A. Sinclair Dunlop has not been actively trading shares of Apellis Pharmaceuticals during the last quarter. Learn More on A. Sinclair Dunlop's trading history.

Who are Apellis Pharmaceuticals' active insiders?

Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Apellis Pharmaceuticals?

During the last twelve months, insiders at the sold shares 52 times. They sold a total of 863,642 shares worth more than $50,338,607.70. The most recent insider tranaction occured on May, 8th when insider Pascal Deschatelets sold 78,907 shares worth more than $3,341,711.45. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.

Information on this page was last updated on 5/8/2024.

A. Sinclair Dunlop Insider Trading History at Apellis Pharmaceuticals

See Full Table

A. Sinclair Dunlop Buying and Selling Activity at Apellis Pharmaceuticals

This chart shows A. Sinclair Dunlop's buying and selling at Apellis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals logo
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $41.11
Low: $39.50
High: $41.58

50 Day Range

MA: $49.18
Low: $39.68
High: $59.71

2 Week Range

Now: $41.11
Low: $19.83
High: $94.75


1,145,036 shs

Average Volume

1,533,352 shs

Market Capitalization

$4.99 billion

P/E Ratio


Dividend Yield